Weimai Showcases AI-Powered Maternal and Child Lifecycle Management Solution on Dongmai New Product Showcase Episode 133

As a leading full-course disease management platform in China, Weimai responds to the Outline for the Development of Women and Children by partnering with public hospitals to integrate departments including reproductive medicine, obstetrics, gynecology, postpartum rehabilitation, child healthcare, pediatrics, anesthesiology, and clinical nutrition. This collaboration establishes a comprehensive lifecycle management service system for women and children, aiming to enhance their healthcare experience, expand service-based medical revenue, and promote the development of fertility-friendly hospitals.

Weimai Healthcare Enhances Maternal and Child Health Management Efficiency with Proprietary CareAI and Full-Course Disease Management Tools, establishing a closed-loop service system covering the entire cycle of “pre-diagnosis, during diagnosis, and post-diagnosis”; on the other hand, by integrating resources from eight major departments including obstetrics and pediatricsSource, extending the service chain for full-lifecycle health management of women and children. Currently,Implemented in over 500 medical institutions, serving an average of 540,000 households annuallycourt; cross-departmental referral rate reached 40%;Finally, Weimai has innovatively developed a “multi-specialist co-management” team service model and established a new service scenario for the “Maternal and Child Health Management Center.” By integrating online and offline services, it enhances patients’ healthcare experience and adds a more compassionate touch to maternal and child health management.

On Tuesday, August 12, VCBeat invitedZhang Le, Executive General Manager of Weimai Medical’s City-level Middle Platform; Zhang Ruiqian, Marketing Director of Weimai Medical; Yang Shuang, Consulting Director of Weimai Medical, three guests presented and shared insights on Weimai’s AI+ comprehensive lifecycle health management for women and children.

Weimai is a digital health company that upholds the philosophy of “Illuminating Medicine with Technology” and fulfills its corporate mission of “Making Healthcare Services Accessible.”

Since its establishment on September 9, 2015, Weimai has been continuously driving the digital and intelligent upgrading of healthcare services, empowering medical institutions and healthcare professionals to provide comprehensive, full-cycle healthcare services for the entire population, thereby meeting the multi-level, diversified, and personalized service needs of the public.

As the pioneer of AI-enabled full-course disease management, Weimai has become China’s largest full-course disease management service platform. By leveraging its proprietary CareAI artificial intelligence technology to drive the scalable application of full-course disease management, Weimai is committed to building a managed care organization (MCO) with Chinese characteristics. The company has secured hundreds of millions of dollars in financing from leading investors, including Yuanjing Capital, Source Code Capital, Matrix Partners China, Qianji Capital, IDG Capital, Baidu Capital, and CITIC Bank Investment. As one of the representative unicorn enterprises in the digital health sector—characterized by high technology, high growth, and high value—Weimai has gained widespread recognition from the government, the industry, and users.

“Artery New Product Launch” is a live-streaming program dedicated to supporting medical enterprises in launching innovative products, with the mission of facilitating the milestone release of every medical innovation.